Related Experiment Video
Updated: Jun 23, 2026
07:56
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
Published on: August 11, 2021
Methamphetamine preconditioning: differential protective effects on monoaminergic systems in the rat brain
Jean Lud Cadet1, Irina N Krasnova, Bruce Ladenheim
1Molecular Neuropsychiatry Branch, National Institute on Drug Abuse/NIH/DHHS, 251 Bayview Boulevard, Baltimore, MD 21224, USA. jcadet@intra.nida.nih.gov
Neurotoxicity Research
|April 23, 2009
Summary
Methamphetamine (METH) preconditioning protects against dopamine depletion but not serotonin or norepinephrine depletion in rat brains. This suggests differential mechanisms of METH toxicity across neurotransmitter systems.
Area of Science:
- Neuroscience
- Pharmacology
- Toxicology
Background:
- Methamphetamine (METH) pretreatment can reduce toxicity from subsequent METH exposure.
- Previous research primarily focused on METH's effects on the striatal dopaminergic system.
Purpose of the Study:
- To investigate the protective effects of a METH preconditioning regimen, mimicking human addiction patterns, on monoaminergic systems in the rat brain.
- To explore potential differences in METH toxicity mechanisms across dopaminergic, serotonergic, and noradrenergic systems.
Main Methods:
- Rats were administered a regimen of gradually increasing METH doses.
- A METH challenge (5 mg/kg x 6 injections, 1 hour apart) was administered.
- Dopamine, serotonin, and norepinephrine levels were measured in the striatum, cortex, and hippocampus.
Main Results:
- METH preconditioning provided complete protection against dopamine depletion in the striatum and cortex.
- No significant protection was observed against METH-induced serotonin depletion in the striatum and hippocampus, though some protection occurred in the cortex.
- No protection was observed against METH-induced norepinephrine depletion in the hippocampus.
Conclusions:
- METH preconditioning exhibits differential protective effects on monoaminergic systems, contrary to current understanding.
- The findings suggest distinct mechanisms underlie METH toxicity in dopaminergic versus serotonergic and noradrenergic systems.
- Further research is needed to elucidate the cellular and molecular basis for these observed differential responses to METH toxicity.
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:15Drug Abuse and Addiction: Pharmacological Phenomena
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...